Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedJul 21, 2026
DataAggregated Company Financials
Companies52
  • 7D-4.2%
  • 3M-2.5%
  • 1Y33.1%
  • YTD-4.8%

Over the last 7 days, the Pharma industry has dropped 4.2%, driven by Curaleaf Holdings declining 7.8%. In contrast, Cardiol Therapeutics has gained 17%. In the past year, the industry has gained 33%. Looking forward, earnings are forecast to grow by 15% annually.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 22 Jul 2026CA$13.5bCA$10.6b-CA$1,722,373,466.699.6x-7.8x1.3x
Fri, 19 Jun 2026CA$13.8bCA$10.7b-CA$1,727,688,816.708.6x-8x1.3x
Sun, 17 May 2026CA$15.6bCA$12.1b-CA$1,895,525,420.558.2x-8.3x1.3x
Tue, 14 Apr 2026CA$13.9bCA$11.3b-CA$1,651,415,940.0213.4x-8.4x1.2x
Thu, 12 Mar 2026CA$13.9bCA$11.2b-CA$1,907,557,970.5712.7x-7.3x1.2x
Sat, 07 Feb 2026CA$14.2bCA$11.2b-CA$1,941,215,725.6316x-7.3x1.3x
Mon, 05 Jan 2026CA$16.5bCA$11.2b-CA$1,942,561,183.2216.6x-8.5x1.5x
Wed, 03 Dec 2025CA$13.9bCA$11.4b-CA$1,932,303,116.3514.5x-7.2x1.2x
Fri, 31 Oct 2025CA$16.0bCA$11.2b-CA$2,037,273,211.5433.3x-7.9x1.4x
Sun, 28 Sep 2025CA$15.3bCA$11.3b-CA$2,043,530,996.5934x-7.5x1.4x
Tue, 26 Aug 2025CA$17.0bCA$11.9b-CA$2,550,325,025.8237.3x-6.7x1.4x
Thu, 24 Jul 2025CA$11.1bCA$11.7b-CA$2,523,026,867.5616.9x-4.4x0.9x
Sat, 21 Jun 2025CA$9.6bCA$11.7b-CA$2,527,295,149.1518x-3.8x0.8x
Mon, 19 May 2025CA$9.1bCA$10.3b-CA$2,189,505,861.0817.5x-4.2x0.9x
Wed, 16 Apr 2025CA$9.0bCA$12.1b-CA$2,582,499,665.1419.3x-3.5x0.7x
Fri, 14 Mar 2025CA$10.9bCA$12.4b-CA$2,655,650,103.5220x-4.1x0.9x
Sun, 09 Feb 2025CA$12.7bCA$12.1b-CA$2,206,618,127.1820.5x-5.7x1x
Tue, 07 Jan 2025CA$13.6bCA$12.1b-CA$2,409,704,539.8428.8x-5.6x1.1x
Thu, 05 Dec 2024CA$13.9bCA$11.9b-CA$2,571,108,625.1322.1x-5.4x1.2x
Sat, 02 Nov 2024CA$18.3bCA$11.9b-CA$2,723,751,968.2718.5x-6.7x1.5x
Mon, 30 Sep 2024CA$18.4bCA$11.6b-CA$2,688,870,642.7527.7x-6.8x1.6x
Wed, 28 Aug 2024CA$18.6bCA$11.5b-CA$2,725,385,465.7222.1x-6.8x1.6x
Fri, 26 Jul 2024CA$20.1bCA$11.8b-CA$3,210,246,231.9220.3x-6.3x1.7x
Sun, 23 Jun 2024CA$19.6bCA$11.8b-CA$3,231,300,250.6417.2x-6.1x1.7x
Tue, 21 May 2024CA$25.0bCA$11.9b-CA$3,482,874,663.9613.8x-7.2x2.1x
Thu, 18 Apr 2024CA$24.2bCA$12.0b-CA$3,479,051,905.128.7x-7x2x
Sat, 16 Mar 2024CA$19.2bCA$11.9b-CA$3,499,996,583.818.9x-5.5x1.6x
Mon, 12 Feb 2024CA$23.3bCA$11.9b-CA$6,801,390,350.3312.1x-3.4x2x
Wed, 10 Jan 2024CA$19.3bCA$12.3b-CA$6,742,078,090.0010x-2.9x1.6x
Fri, 08 Dec 2023CA$19.7bCA$12.4b-CA$6,785,821,946.008.5x-2.9x1.6x
Sun, 05 Nov 2023CA$16.1bCA$12.4b-CA$7,313,471,152.0011.6x-2.2x1.3x
Tue, 03 Oct 2023CA$20.0bCA$12.4b-CA$7,336,437,455.0015.5x-2.7x1.6x
Thu, 31 Aug 2023CA$15.5bCA$12.9b-CA$7,869,696,339.0013.9x-2x1.2x
Sat, 29 Jul 2023CA$14.3bCA$13.2b-CA$9,713,979,724.0012.4x-1.5x1.1x
Price to Earnings Ratio

-1.5x


Total Market Cap: CA$14.3bTotal Earnings: -CA$9,713,979,724.00Total Revenue: CA$13.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -5.8x202420252026
Current Industry PE
  • Investors are relatively neutral on the Canadian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 1.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 6.9% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?

CA Market-0.75%
Healthcare-2.56%
Pharma-4.21%
Pharma-4.21%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
APTX Apotex HealthCA$39.674.4%
+CA$381.6m		n/aPE24.3x
CRON Cronos GroupCA$3.972.1%
+CA$29.9m		36.4%PS6.6x
GUD Knight TherapeuticsCA$9.971.7%
+CA$16.7m		63.2%PE174.5x
CRDL Cardiol TherapeuticsCA$1.778.6%
+CA$16.1m		-5.9%PB8.4x
OGI Organigram GlobalCA$1.325.6%
+CA$9.9m		-37.4%PS0.7x

Latest News

OGI
CA$1.32
Organigram Global
7D
5.6%
1Y
-37.4%
OPTI
CA$6.56
Optimi Health
7D
13.1%
1Y
32.5%
VREO
CA$13.76
Vireo Growth
7D
-2.4%
1Y
-24.8%
HITI
CA$3.11
High Tide
7D
2.0%
1Y
-4.9%
APTX
CA$39.67
Apotex Health
7D
4.4%
1Y
n/a
TSND
CA$0.77
TerrAscend
7D
-9.4%
1Y
54.0%
CRON
CA$3.97
Cronos Group
7D
2.1%
1Y
36.4%
CURA
CA$13.52
Curaleaf Holdings
7D
-2.5%
1Y
178.2%
VRNO
CA$7.95
Verano Holdings
7D
-3.0%
1Y
96.3%
Narrative Update • Jul 14

VRNO: Florida Expansion And DEA Rescheduling Pathway Will Drive Future Upside

Analysts have lifted their price target for Verano Holdings to CA$28.33 from CA$5.06, citing updated assumptions around discount rates, revenue growth, profit margins, and a revised future P/E multiple. What's in the News Verano Holdings announced a planned 1 for 5 stock split or significant stock dividend scheduled for June 11, 2026.
CL
CA$1.00
Cresco Labs
7D
-9.1%
1Y
20.5%
GTII
CA$9.91
Green Thumb Industries
7D
-6.1%
1Y
24.0%
Narrative Update • Jul 09

GTII: Partial Rescheduling Order Will Support Future Upside In Key Markets

Analysts have raised their CA$ fair value estimate for Green Thumb Industries from CA$17.30 to CA$18.45, citing updated assumptions around discount rates, profit margins, and a higher future P/E multiple following recent sector commentary on cannabis rescheduling and company-specific research. Analyst Commentary Recent Street research on Green Thumb Industries has highlighted both supportive and cautious views around the stock's valuation, particularly in light of sector commentary on cannabis rescheduling.
GUD
CA$9.97
Knight Therapeutics
7D
1.7%
1Y
63.2%
Narrative Update • Jul 09

GUD: Higher Discount Rate Will Likely Expose Execution Risk Ahead

Analysts have raised their fair value estimate for Knight Therapeutics from CA$6.15 to CA$9.00, citing recent price target adjustments and renewed coverage that reflect updated views on the discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research coverage of Knight Therapeutics highlights a mix of optimism around the revised fair value estimate and pockets of caution around execution and valuation risk.
NVRS
CA$1.21
Noveris Health Sciences
7D
-21.4%
1Y
384.0%
GRIN
CA$0.59
Grown Rogue International
7D
-9.2%
1Y
5.4%
FNT.U
US$0.025
FLUENT
7D
25.0%
1Y
-64.3%
CRDL
CA$1.77
Cardiol Therapeutics
7D
8.6%
1Y
-5.9%
Analysis Article • Jun 04

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...